Journal of Neuroinfectious Diseases
ISSN: 2314-7326

Zhou, J Neuroinfect Dis 2025, 16:2

Mini Review Open Access

Psychopharmacology of Schizophrenia: Understanding Drug Treatments and Mechanisms

Zhou Bo*

Department of Epidemiology & Public Health, Central University of Finance and Economics, China

Introduction

Schizophrenia is a chronic, severe mental disorder characterized by disturbances in thought processes, emotions, and behaviors. It affects approximately 1% of the global population and significantly impairs social and occupational functioning. While the exact cause of schizophrenia remains unclear, it is believed to result from a complex interplay of genetic, neurobiological, and environmental factors. The primary treatment for schizophrenia involves pharmacological interventions, particularly antipsychotic medications, which help alleviate symptoms and improve the quality of life for patients. This article explores the psychopharmacology of schizophrenia, focusing on drug mechanisms, efficacy, side effects, and emerging treatment options. Schizophrenia is a severe and chronic mental disorder that affects perception, cognition, and behavior. It is characterized by positive symptoms such as hallucinations and delusions, negative symptoms including social withdrawal and emotional flattening, and cognitive deficits that impair daily functioning. The exact cause of schizophrenia remains unclear, but it is believed to result from a combination of genetic, neurobiological, and environmental factors. One of the primary hypotheses regarding its pathophysiology is the dopamine hypothesis, which suggests that overactivity in the mesolimbic dopamine system contributes to positive symptoms, while underactivity in the prefrontal cortex is associated with negative and cognitive symptoms. Psychopharmacological treatment of schizophrenia primarily relies on antipsychotic medications, which are divided into first-generation (typical) and second-generation (atypical) antipsychotics [1,2]. First-generation antipsychotics, such as haloperidol and chlorpromazine, primarily block dopamine D2 receptors and are effective in reducing psychotic symptoms but often cause severe motor side effects, known as extrapyramidal symptoms (EPS). Second-generation antipsychotics, including clozapine, risperidone, and aripiprazole, target both dopamine and serotonin receptors, offering broader symptom relief with a lower risk of EPS but posing metabolic risks such as weight gain and diabetes [3,4].

Discussion

Schizophrenia is a complex psychiatric disorder that requires a multifaceted treatment approach, with antipsychotic medications being the primary pharmacological intervention. These drugs primarily target dopaminergic and serotonergic neurotransmission, aiming to alleviate symptoms while minimizing adverse effects [5]. However, despite significant advancements in treatment, challenges remain in addressing treatment resistance, side effects, and negative and cognitive symptoms.

Dopaminergic System and Antipsychotics

The dopamine hypothesis remains central to schizophrenia pharmacotherapy. Excessive dopamine activity in the mesolimbic pathway is associated with positive symptoms (hallucinations, delusions), while dopamine deficits in the prefrontal cortex contribute to negative and cognitive symptoms. First-generation antipsychotics (FGAs), such as haloperidol and chlorpromazine, exert their effects by blocking dopamine D2 receptors, effectively reducing positive symptoms. However, their strong D2 blockade in the nigrostriatal pathway leads to extrapyramidal symptoms (EPS), such as dystonia, akathisia, and tardive dyskinesia, limiting their long-term use [6].

To overcome these limitations, second-generation antipsychotics (SGAs), including risperidone, olanzapine, and clozapine, were developed. SGAs block both dopamine D2 and serotonin 5-HT2A receptors, allowing for dopamine modulation in different brain regions [7]. This dual action improves treatment outcomes by reducing positive symptoms while also addressing negative symptoms. However, SGAs introduce their own risks, such as weight gain, metabolic syndrome, and diabetes, particularly with clozapine and olanzapine. Clozapine remains the most effective treatment for treatment-resistant schizophrenia, but its use is limited by the risk of agranulocytosis, requiring regular blood monitoring.

Limitations of Dopamine-Based Treatments

While first-generation antipsychotics (FGAs) effectively reduce positive symptoms by blocking dopamine D2 receptors, they fail to address negative and cognitive symptoms and often cause severe extrapyramidal side effects (EPS). Second-generation antipsychotics (SGAs) improve on this by targeting serotonin 5-HT2A receptors in addition to dopamine D2, reducing EPS risk and improving negative symptoms. However, SGAs introduce metabolic concerns such as weight gain, diabetes, and cardiovascular risks, particularly with drugs like olanzapine and clozapine [8]. Clozapine remains the gold standard for treatment-resistant schizophrenia, but its risk of agranulocytosis limits widespread use. Additionally, many patients experience only partial symptom relief, highlighting the need for alternative pharmacological strategies.

Emerging Pharmacological Approaches

Despite existing treatments, many patients continue to experience persistent negative and cognitive symptoms. Third-generation antipsychotics (TGAs), such as aripiprazole and cariprazine, function as dopamine partial agonists, balancing dopamine activity rather than fully blocking it. These drugs offer fewer motor side effects and better cognitive outcomes [9].

Beyond dopamine, glutamatergic dysfunction has been implicated

***Corresponding author:** Zhou Bo, Department of Epidemiology & Public Health, Central University of Finance and Economics, China, Email: zhau@bo.cn

Received: 03-Mar-2025, Manuscript No: JNID-25-162528, **Editor Assigned:** 07-Mar-2025, Pre QC No: JNID-25-162528 (PQ), **Reviewed:** 18-Mar-2025, QC No: JNID-25-162528, **Revised:** 22-Mar-2025, Manuscript No: JNID-25-162528 (R), **Published:** 29-Mar-22025, DOI: 10.4172/2314-7326.1000559

Citation: Zhou B (2025) Psychopharmacology of Schizophrenia: Understanding Drug Treatments and Mechanisms. J Neuroinfect Dis 16: 559.

in schizophrenia. Drugs targeting NMDA receptor function, such as glycine transporter inhibitors (sarcosine) and metabotropic glutamate receptor modulators, are being explored for their ability to improve negative and cognitive symptoms. Additionally, anti-inflammatory agents, neuromodulatory techniques, and psychedelic-assisted therapy (e.g., ketamine) are emerging as potential adjunctive treatments [10].

Antipsychotic Medications

Antipsychotics are the cornerstone of schizophrenia treatment and are categorized into two main classes:

Mechanism of Action:

D2 receptor antagonism in the mesolimbic pathway reduces positive symptoms.

However, D2 blockade in the nigrostriatal pathway leads to extrapyramidal symptoms (EPS) such as dystonia, akathisia, and tardive dyskinesia.

Dopamine blockade in the tuberoinfundibular pathway increases prolactin levels, leading to side effects like gynecomastia and menstrual irregularities.

Side Effects:

Weight gain, metabolic syndrome, and diabetes risk (especially with olanzapine and clozapine)

Sedation and orthostatic hypotension

Increased prolactin levels (seen with risperidone)

Clozapine-specific risks: Agranulocytosis (requires regular blood monitoring), myocarditis, seizures

Newer and Emerging Treatments

Research into schizophrenia pharmacotherapy continues to evolve, with newer drugs targeting multiple neurotransmitter systems beyond dopamine and serotonin.

Glutamatergic Modulators

Given the role of glutamate dysregulation in schizophrenia, drugs targeting NMDA and AMPA receptors are under investigation.

Sarcosine, a glycine transporter inhibitor, has shown promise in improving negative symptoms.

Anti-Inflammatory and Neuromodulatory Approaches

Minocycline (an antibiotic with anti-inflammatory properties) and Omega-3 fatty acids are being studied for their potential neuroprotective effects.

Transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS) are also being explored as adjunct therapies.

Challenges and Future Directions

Despite significant advances, schizophrenia treatment remains challenging due to:

Treatment resistance: About 30% of patients do not respond adequately to current antipsychotics.

Side effects: Many patients experience severe metabolic and neurological adverse effects, leading to poor medication adherence.

Limited efficacy for negative and cognitive symptoms: Existing medications primarily target positive symptoms, leaving other core aspects of schizophrenia untreated.

Future research aims to:

Develop personalized medicine based on genetic and biomarker profiles.

Explore psychedelic-assisted therapy (e.g., ketamine) for symptom relief.

Investigate non-dopaminergic drugs to address negative and cognitive symptoms more effectively.

Conclusion

The psychopharmacology of schizophrenia is centered around antipsychotic medications, which primarily modulate dopamine and serotonin neurotransmission. First-generation antipsychotics effectively reduce positive symptoms but carry a high risk of motor side effects, while second-generation antipsychotics offer a better balance but pose metabolic challenges. Emerging therapies, including glutamatergic modulators and neuromodulatory techniques, hold promise for addressing the limitations of current treatments. As research advances, the goal remains to develop more effective, personalized, and well-tolerated treatments to improve the lives of individuals with schizophrenia.

References

1. Kennedy PG, Steiner I (2013) Recent issues in herpes simplex encephalitis. J Neurovirol 19: 346-350.
2. Corey L, Adams H G, Brown Z A, Holmeset KK (1983)Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 98: 958
3. Whitley RJ, Gnann JW (2002)Viral encephalitis: familiar infections and emerging pathogens. Lancet 359: 507–513.
4. Forshey BM, Guevara C , Laguna-Torres A , Cespedes M , Vargas J, et al. (2010) Arboviral etiologies of acute febrile illnesses in Western South America, 2000–2007. PLoS Negl Trop Dis 4: e787.
5. Espinoza IO (2011)Enteroviral central nervous system infections in children treated at a hospital in Lima, Peru. Rev Peru Med Exp Salud Publica 28: 602-609.
6. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7: 365-8.
7. Oger J, Frykman H (2015) An update on laboratory diagnosis in myasthenia gravis. Clin Chim Acta 449: 43-48.
8. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, et al. (2008) IgG1 antibodies to acetylcholine receptors in 'seronegative'myasthenia gravis. Brain 131: 1940-1952.
9. Pevzner A, Schoser B, Peters K, Cosma N-C, Karakatsani A, et al. (2012) Anti-LRP4 autoantibodies in AChR-and MuSK-antibody-negative myasthenia gravis. J Neurol259: 427-435.
10. Gasperi C, Melms A, Schoser B, Zhang Y, Meltoranta J, et al. (2014)Anti-agrin autoantibodies in myasthenia gravis. Neurology 82: 1976-1983.